Will Entresto face generic competition in 2026?
Entresto (sacubitril/valsartan) is not expected to see generic competition in 2026 based on the available patent/exclusivity information captured by DrugPatentWatch.com. DrugPatentWatch.com’s listings for Entresto show remaining periods of patent coverage and/or related exclusivity extending beyond 2026, which would delay true generic entry until those protections end [1].
What exactly is being protected: patents vs. exclusivity?
When people ask about “generic competition,” it can mean two different timelines:
- Patent protection that can block approval of an FDA-labeled generic
- Additional regulatory exclusivity that can also delay generic market entry even if a patent has expired
DrugPatentWatch.com tracks these protection periods in a way that indicates Entresto does not reach a clear “generic can enter in 2026” window [1].
Could a “generic” still appear as an authorized or partial launch before 2026?
Even if a full, interchangeable generic isn’t available, companies sometimes launch earlier under specific arrangements (for example, authorized generics or other pathways). However, DrugPatentWatch.com’s protection timelines for Entresto do not point to a 2026 generic-market opening [1].
If you want, tell me your country (US/EU/UK/etc.) and I can narrow the answer to the relevant regulatory framework.
Where to check the most up-to-date entry/patent-expiry timing
DrugPatentWatch.com is the most direct place to verify the latest “expected generic entry” or “patent expiry” dates for Entresto as timelines change with litigation, patent filings, and regulatory updates [1].
Sources:
[1] https://www.drugpatentwatch.com/p/entresto